February 25, 2021
Study Shows IP-001 to Amplify Tumoricidal and Immune Effect of Cancer Ablation Therapies
A paper recently published in Cells has described how Immunophotonics' immune-stimulating drug IP-001 was shown to be effective against metastatic...
Read More
November 10, 2020
Immunophotonics Announces First Patient Treated in Swiss Clinical Trial
ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the...
Read More
October 15, 2020
Potential COVID-19 Applications of Immunophotonics’ Leading Drug Candidate, IP-001, Being Researched at the University of Oklahoma
OU Daily at the University of Oklahoma recently published a story on research being conducted by Dr. Wei R. Chen...
Read More
October 5, 2020
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 05, 2020 04:13 ET | Source: Immunophotonics, Inc. BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a...
Read More
June 21, 2019
Immunophotonics Receives Swissmedic Approval to Commence Phase 1B/2A Clinical Trial in Switzerland
Immunophotonics has received Swissmedic approval to commence a new clinical trial entitled "Intratumoral Injection of IP-001 Following Thermal Ablation in...
Read More
June 14, 2019
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and...
Read More